Investigating new natural compounds for treating high grade serous ovarian cancer
Pharmacological Potential of Combined Translation and Autophagy Inhibition in High Grade Serous Ovarian Cancer
This study is looking at two natural compounds that might help treat high grade serous ovarian cancer, which is a tough type of cancer to beat, and it aims to find out if these compounds can safely help kill cancer cells and improve treatment options for patients like you.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-10946931 on NIH RePORTER |
What this research studies
This research focuses on high grade serous ovarian cancer, the most lethal form of ovarian cancer, which often becomes resistant to current treatments. The study aims to evaluate the effectiveness of two natural compounds, didesmethylrocaglamide and phyllanthusmin34, which have shown promise in inducing cancer cell death through different mechanisms. By understanding how these compounds work, the research seeks to develop new therapeutic strategies that could improve outcomes for patients with this aggressive cancer. Patients may be involved in trials to assess the safety and efficacy of these treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with high grade serous ovarian cancer, particularly those who have not responded well to existing therapies.
Not a fit: Patients with other types of ovarian cancer or those who are not diagnosed with cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients suffering from high grade serous ovarian cancer.
How similar studies have performed: Other research has shown promise in using natural compounds for cancer treatment, indicating potential for success with this approach.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Kaweesa, Elizabeth — University of Illinois at Chicago
- Study coordinator: Kaweesa, Elizabeth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.